Jiangxi Ruijin Sanjiu Pharmaceutical Co.
Jiangxi Qingfeng Pharmaceutical Co.
Jiangxi Chuanlong Industrial Co.
Jiangxi Qiaoye Pharmaceutical Co.
Jiangxi Gannan Pharmaceutical Factory
Jiangxi Gannan Haixin Pharmaceutical Co.
Ganzhou Ouxin Pharmaceutical Technology Development Co.
Jiangxi Lifike Pharmaceutical Co.
1. Pharmaceutical enterprises are enterprises in the pharmaceutical industry, which can be categorized into drug manufacturers and drug business enterprises. According to the People's Republic of China *** and the State Drug Administration Law (hereinafter referred to as the "Drug Administration Law"), Article 102 of the definition of the drug production enterprise is engaged in the production of drugs licensed enterprises or part-time business enterprises. A drug business enterprise is a franchised enterprise or part-time business enterprise engaged in the operation of drugs.
2, after a long period of sustained high-speed growth, affecting the development of China's pharmaceutical industry, a variety of contradictions gradually revealed, China's pharmaceutical industry has entered a crisis and turnaround coexist in the critical period of development. The future of China's pharmaceutical industry will be how the development of the market competition pattern will evolve, how the pharmaceutical enterprises will respond to a new round of market competition and reshuffle.
3, the risk of drug price reductions, which has been a problem in the pharmaceutical industry, especially with the deepening of health insurance fee control, the trend of fee control is more obvious. Therefore, when choosing investment products, we must pay attention to the pricing power of the enterprise. If the company itself has no pricing power and no cost advantage, it is obviously difficult to obtain profit margins above the industry average.
4, patent challenges this risk mainly exists in the original drug R & D enterprises. Currently there are relatively few APIs on the market in China. However, with the development of the pharmaceutical industry, there are more and more original drug research conference, so there will be more and more patent litigation and challenges. Enterprises must have a team of specialized attorneys, or they will face years of continuous patent litigation.
5, the risk of new product substitution, new product substitution often occurs in pharmaceutical companies, equipment and medical services are not involved in substitution. Every few years drugs will be upgraded. Once the emergence of new drugs with better efficacy and fewer side effects, the old products will face the risk of being replaced, and even the market may shrink dramatically to zero, so we have to pay close attention to product trends in the industry.